WHITEPAPER

Tech-enabled Prior Authorization

Measuring ROI from automation and ePA

A metrics framework for oncology, rare disease, and CNS therapies

Prior Authorization is a key bottleneck affecting time-to-therapy, patient conversion, and revenue outcomes in oncology, rare disease, and CNS therapies. While ePA and automation can streamline processes, their value remains difficult to demonstrate without measurable outcomes. This whitepaper presents a practical metrics framework to help organizations evaluate tech-enabled Prior Authorization across process efficiency, clinical and access impact, and operational ROI.

Read this whitepaper to:

Understand why measuring ROI is critical as Prior Authorization complexity and specialty therapy volumes grow.
Explore a three-layer metrics framework covering process efficiency, clinical and access impact, and operational ROI.
Identify the metrics that matter, from PA cycle time and straight-through processing to approval rates, abandonment, and cost-to-serve.
Learn how ROI manifests differently across oncology, rare disease, and CNS therapies.
Explore directional benchmarks for manual and ePA-enabled Prior Authorization performance.
Understand how access, commercial, and IT teams can share ownership of outcomes.
Discover how measurement, dashboards, and leadership visibility can support the transition from automation to enterprise scale.
See real-world examples of PA automation and their impact on speed, productivity, denials, and patient access.

Move beyond measuring automation. Measure the outcomes that make it valuable

Frequently Asked Questions

How does automation improve Prior Authorization (PA) efficiency?

Automation improves PA efficiency by removing manual, repetitive work from documentation review, submission, and payer communication. This cuts cycle time and lifts straight-through processing rates in mature programs.

What process efficiency metrics are critical for Prior Authorization (PA)?

The critical process efficiency metrics are end-to-end PA cycle time, straight-through processing (STP) rate, and resubmission avoidance rate. Together, they show how fast, automated, and accurate the PA process is, with mature programs reaching STP rates of 60-75%.

What are common challenges in manual Prior Authorization (PA) processes?

Manual PA processes are slowed by heavy documentation review, frequent Payer clarifications, and inconsistent ePA adoption. These bottlenecks are labor-intensive and error-prone, driving up costs and delaying therapy starts.

How do you measure the operational impact of your Prior Authorization (PA) automation?

Operational impact is measured through cost-to-serve per case, capacity uplift, and denial-related cost avoidance. Leading programs applying these metrics report 25-40% reductions in cost-to-serve and 20-30% productivity gains.

How do you ensure data security in your Prior Authorization (PA) automation platforms?

Data security in PA automation relies on encrypted data in transit and at rest, role-based access controls, and continuous compliance monitoring aligned with HIPAA. FHIR-based ePA solutions add strict authentication and audit trails so patient data stays protected across the interoperability layer.

How do you scale Prior Authorization (PA) automation beyond your initial pilot?

Scaling beyond a pilot starts with embedding metrics from day one, since unmeasured pilots are hard to prove or replicate. Dashboards and governance need to evolve alongside the program as it grows. Consult with CitiusTech experts to design a scaling roadmap from pilot to enterprise.

How do you plan to move from measuring process efficiency to capturing broader clinical and business outcomes?

The path runs through a three-layer framework: process efficiency metrics like cycle time, clinical impact metrics like Time-to-Therapy, and operational ROI metrics like cost-to-serve. Layering these together links a faster workflow to measurable patient and business outcomes.

How do you ensure that your Prior Authorization processes are aligned with your organization's strategic goals for access and efficiency?

cycle time and abandonment, commercial teams own approval and therapy initiation, and IT owns automation reliability and data quality. Consult with CitiusTech experts to set up the ownership and governance model that connects PA performance to enterprise goals.

What directional benchmarks do you set for manual versus ePA-enabled Prior Authorization performance in your organization?

Directional benchmarks compare manual and ePA-enabled performance: PA cycle time drops from 15-30 days to 24-72 hours, approval rate rises from 55-70% to 75-90%, and abandonment rate falls from 10-18% to 5-10%. These ranges are directional, so organizations should set their own baselines.